Sequential treatment with Lm-ANXA2 and anti-PD-1 blockade antibody in genetically engineered KPC mice with spontaneous PDAC tumors resulted in greater tumor response
| Treatment Group | Interval decrease in tumor size before day 22 | P value |
| Lm-ANXA2 | 2/11 (18%) | Reference |
| Untreated | 1/10 (10%) | NS |
| Empty Lm | 2/12 (17%) | NS |
| Treatment Group | Interval decrease in tumor size after day 22 | P value |
| Lm-ANXA2 + anti-PD-1 | 8/10 (80%) | Reference |
| Untreated | 1/8 (13%) | p = 0.015 |
| Empty Lm | 2/11 (18%) | p = 0.009 |
Percentages of mice with interval decreases in tumor size measured by ultrasound before and after Day 22 in untreated KPC mice (n = 10), KPC mice treated with Empty
Lm (n = 12), and KPC mice treated with Lm-ANXA2 followed by anti-PD-1 antibodies (n = 12). ** p < 0.01; ***p < 0.001; ns, not significant. Comparison between percentages of mice with interval decreases in tumor size before vs. after Day 22 has a p value of 0.009